Atara Biotherapeutics Board Shake-Up: Sales Trigger
Greg Ciongoli just took the reins at Atara Biotherapeutics. Pitch your Regulatory Intelligence Platform and cost-benchmarking now. Turbocharge deal flow and hit your commission.
Published on
Do not index
Do not index
🚀 Battle Card: Atara Biotherapeutics, Inc.
Quick trigger:
👤 Decision Maker in the News
- Greg Ciongoli, Chair of the Board of Directors · 🔗 LinkedIn
💡 Why It Matters
- New board leadership under Greg suggests a refocused push on Ebvallo milestones and BLA progress, making this Atara Biotherapeutics sales trigger a prime moment to pitch regulatory and cost optimization solutions. → Source
🎯 Core Pain Point
- Maximizing value from Ebvallo milestones and royalties
- Securing FDA approval of resubmitted BLA within a tighter budget
💰 What to Pitch
- Primary: Regulatory Intelligence Platform → Accelerate BLA review & approval timelines
- Expansion: Operational Cost Benchmarking → Identify $ savings and optimize R&D spend
🗺️ Quick Context
- HQ: Thousand Oaks, CA
- Employees: ≈ 23
- Rev: ≈ $10 M
- Website: https://www.atarabio.com/
🤼 Competitive Intel
Which other vendors you’ll probably face to win Atara Biotherapeutics, Inc.’s business.
- Parexel — Regulatory Consulting
- Unique edge: Global FDA submission expertise for advanced therapies
- Evaluated by Board Chair & VP R&D
- IQVIA — Clinical Development
- Unique edge: Integrated data analytics & trial ops for cell therapy
- Evaluated by VP Clinical for trial acceleration
- Lonza — Cell Therapy Manufacturing
- Unique edge: Scalable allogeneic production capabilities
- Evaluated by COO for cost-effective GMP supply
✅ Do-Now Checklist
Connect with Greg Ciongoli on LinkedIn (link above)
Craft email/DM referencing this Atara Biotherapeutics sales trigger and offer Regulatory Intelligence Platform
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get this Atara Biotherapeutics sales trigger intel daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑❑
OFFER_BRIEF = ❑Regulatory Intelligence Platform❑
PROOF_METRIC = ❑≈ 30% faster approval times❑
CTA_STYLE = ❑quick_call | case_study❑
TONE = ❑friendly | punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Greg
COMPANY = Atara Biotherapeutics, Inc.
DEPT = Board of Directors
SIZE = 23
BOTTLENECK = Maximizing value from Ebvallo milestones and royalties
EVENT = Changes to Board Leadership
DETAIL = Greg Ciongoli assumes Chair of the Board
PAIN = Securing FDA approval of resubmitted BLA within a tighter budget
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250903414165&div=41152219
SIM_CO = ≈ TBD
WIN_METRIC = ≈ TBD
NEXT_SIZE = ≈ TBD
EMP_EST = ≈ 23
REV_EST = ≈ $10M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 23-person Board of Directors
Greg—noticed your Board of Directors team is ≈ 23.
That’s when Maximizing value from Ebvallo milestones and royalties slows growth.
We helped ≈ TBD fix this with Regulatory Intelligence Platform.
Result: ≈ TBD.
Quick call?
PS—next bottleneck hits ≈ TBD.
DM ≤45 words, TONE:
Saw your post about Greg Ciongoli assumes Chair of the Board — Securing FDA approval of resubmitted BLA within a tighter budget.
Regulatory Intelligence Platform. ≈ 30% faster approval times.
Quick chat?